Arrowhead Pharmaceuticals Inc (ARWR)

Pretax margin

		Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019
Earnings before tax but after interest (EBT) (ttm)	US$ in thousands	-602,260	-539,924	-471,335	-297,360	-202,491	-176,563	-146,405	-150,714	-172,278	-153,924	-111,802	-182,986	-140,846	-125,904	-109,591	-102,609	-84,551	-24,242	9,705	53,438
Revenue (ttm)	US$ in thousands	3,551	14,386	25,053	166,263	225,258	245,998	267,743	278,338	243,231	249,939	263,418	144,424	138,288	107,638	89,123	79,841	87,993	123,653	138,974	163,593
Pretax margin		-16,960.29%	-3,753.12%	-1,881.35%	-178.85%	-89.89%	-71.77%	-54.68%	-54.15%	-70.83%	-61.58%	-42.44%	-126.70%	-101.85%	-116.97%	-122.97%	-128.52%	-96.09%	-19.60%	6.98%	32.67%

September 30, 2024 calculation

Pretax margin = EBT (ttm) ÷ Revenue (ttm)
= $-602,260K ÷ $3,551K
= -16,960.29%

Arrowhead Pharmaceuticals Inc's pretax margin has been negative in most recent quarters, indicating that the company's expenses exceed its revenues before accounting for taxes. The pretax margin has shown a deteriorating trend over the past few quarters, with progressively larger negative percentages. This suggests that the company is facing challenges in managing its costs relative to its income, leading to significant operating losses.

Furthermore, the pretax margin figures fluctuate widely, ranging from -16,960.29% to 32.67%, indicating inconsistency in the company's financial performance. The negative pretax margins in several consecutive quarters raise concerns about the company's profitability and financial stability.

Overall, Arrowhead Pharmaceuticals Inc's pretax margin indicates significant financial challenges and inefficiencies in managing costs, highlighting the need for strategic improvements to enhance profitability and sustainability.